TABLE 3.
Number and proportion of patients who were exposed to each antibiotic, followed by the weighted proportion of antibiotic daysa
| Antibiotic treatment | RVP (n = 93) |
RPP (n = 156) |
||||
|---|---|---|---|---|---|---|
| No. of subjects | Exposed (%) | Weighted (%) | No. of subjects | Exposed (%) | Weighted (%) | |
| Penicillins | ||||||
| Piperacillin-tazobactam | 34 | 36.6 | 18.0 | 40 | 25.6 | 15.0 |
| Ampicillin-sulbactam* | 7 | 7.5 | 2.9 | 12 | 7.7 | 5.1 |
| Cephalosporins | ||||||
| Ceftriaxone | 41 | 44.1 | 14.6 | 47 | 30.1 | 13.8 |
| Cefepime | 8 | 8.6 | 2.6 | 7 | 4.5 | 1.5 |
| Vancomycin | 39 | 41.9 | 15.7 | 51 | 32.7 | 16.6 |
| Atypical coverage** | 76 | 81.7 | 42.4 | 125 | 80.1 | 45.9 |
| Azithromycin | 70 | 75.3 | 33.6 | 91 | 58.3 | 28.2 |
| Doxycycline | 5 | 5.4 | 2.2 | 13 | 8.3 | 4.9 |
| Fluoroquinolones | 18 | 19.4 | 6.6 | 41 | 26.3 | 12.8 |
| Other | 8 | 8.6 | 3.8 | 8 | 5.1 | 2.1 |
a
The weighted proportion was calculated by dividing the total patient days of each respective antibiotic by cumulative antibiotic days for each time period. *, Patients who received amoxicillin-clavulanate were also included in this category. **, Atypical coverage includes azithromycin, doxycycline, or fluoroquinolones.